Brief: Lisata Therapeutics Q3 EPS USD -0.65
02/11/2023 21:45
Nov 2 (Reuters) - Lisata Therapeutics Q3 operating expenses USD 5.964 million. * Q3 operating income USD -5.964 million * Q3 EPS USD -0.65 * Q3 net income USD -5.261 million
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Lisata Therapeutics Announces New Method Of Use Patent Granted For Certepetide In The Treatment Of Pancreatic Cancer And Other Solid Tumors
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE -Expeditors International, Waters, Ameresco